Tuberculosis vaccines: Beyond bacilli Calmette-Guérin

Philosophical Transactions of the Royal Society B: Biological Sciences

Volumn 366, Issue 1579, 2011, Pages 2782-2789

  McShane, Helen ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Bacille Calmette Gu rin; Clinical trials; Efficacy; Immune correlates; Tuberculosis; Vaccine

Indexed keywords

BACTERIUM; CAUSE OF DEATH; DISEASE TREATMENT; DRUG DEVELOPMENT; EPIDEMIC; IMMUNE RESPONSE; IMMUNITY; INFECTIOUS DISEASE; RECOMBINATION; TUBERCULOSIS; VACCINATION; VACCINE;

BACILLI (CLASS); MYCOBACTERIUM BOVIS; MYCOBACTERIUM TUBERCULOSIS;

BCG VACCINE; LIVE VACCINE; RECOMBINANT VACCINE;

CELLULAR IMMUNITY; CLINICAL TRIAL (TOPIC); DRUG DESIGN; HUMAN; IMMUNIZATION; IMMUNOLOGY; MICROBIOLOGY; MYCOBACTERIOSIS; MYCOBACTERIUM; PREVENTIVE HEALTH SERVICE; REVIEW; VACCINATION;

BCG VACCINE; CLINICAL TRIALS AS TOPIC; DRUG DESIGN; HUMANS; IMMUNITY, CELLULAR; IMMUNIZATION PROGRAMS; IMMUNIZATION, SECONDARY; MYCOBACTERIUM; MYCOBACTERIUM INFECTIONS; TUBERCULOSIS VACCINES; VACCINATION; VACCINES, ATTENUATED; VACCINES, SYNTHETIC;

EID: 80052515865     PISSN: 09628436     EISSN: 14712970     Source Type: Journal    
DOI: 10.1098/rstb.2011.0097     Document Type: Review

References (66)

1. World Health Organization 2010 Global tuberculosis control. Geneva, Switzerland: WHO Press.
2. World Health Organization 2011 The global plan to stopTB 2011-2015. See http://www.stoptb.org/assets/documents/global/plan/TB_GlobalPlanToStopTB2011-2015.pdf.
3. Rodrigues, L. C., Diwan, V. K. & Wheeler, J.G. 1993 Protective effect of BCG against tuberculous meningitis and miliary tuberculosis: a meta-analysis. Int. J. Epidemiol. 22, 1154-1158. (doi:10.1093/ije/22.6.1154)
4. Sterne, J. A., Rodrigues, L. C. & Guedes, I. N. 1998 Does the efficacy of BCG decline with time since vaccination? Int. J. Tuberc. Lung Dis. 2, 200-207.
5. Trunz, B. B., Fine, P. & Dye, C. 2006 Effect of BCG vaccination on childhood tuberculous meningitis and miliary tuberculosis worldwide: a meta-analysis and assessment of cost-effectiveness. Lancet 367, 1173-1180. (doi:10.1016/S0140-6736(06)68507-3)
6. Stanley, S. J., Howland, C., Stone, M. M. & Sutherland, I. 1981 BCG vaccination of children against leprosy in Uganda: final results. J. Hyg (Lond). 87, 233-248. (doi:10.1017/S002217240006945X)
7. Colditz, G. A., Brewer, T. F., Berkey, C. S., Wilson, M. E., Burdick, E., Fineberg, H. V. & Mosteller, F. 1994 Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature. JAMA 271, 698-702. (doi:10.1001/jama.271.9.698)
8. Rodrigues, L. C. et al. 2005 Effect of BCG revaccination on incidence of tuberculosis in school-aged children in Brazil: the BCG-REVAC cluster-randomised trial. Lancet 366, 1290-1295. (doi:10.1016/S0140-6736 (05)67145-0)
9. Flynn, J. L. & Chan, J. 2001 Immunology of tuberculosis. Annu. Rev. Immunol. 19, 93-129. (doi:10.1146/ annurev.immunol.19.1.93)
10. Caruso, A. M., Serbina, N., Klein, E., Triebold, K., Bloom, B. R. & Flynn, J. L. 1999 Mice deficient in CD4 T cells have only transiently diminished levels of IFN-gamma, yet succumb to tuberculosis. J. Immunol. 162, 5407-5416.
11. Flynn, J. L., Chan, J., Triebold, K. J., Dalton, D. K., Stewart, T. A. & Bloom, B. R. 1993 An essential role for interferon gamma in resistance to Mycobacterium tuberculosis infection. J. Exp. Med. 178, 2249-2254. (doi:10.1084/jem.178.6.2249)
12. Newport, M. J., Huxley, C. M., Huston, S., Hawrylowicz, C. M., Oostra, B. A., Williamson, R. & Levin, M. 1996 A mutation in the interferon-gamma-receptor gene and susceptibility tomycobacterial infection. N. Engl. J. Med. 335, 1941-1949. (doi:10.1056/NEJM199612263352602)
13. Flynn, J. L., Goldstein, M. M., Chan, J., Triebold, K. J., Pfeffer, K., Lowenstein, C. J., Schreiber, R., Mak, T. W. & Bloom, B. R. 1995 Tumor necrosis factor-alpha is required in the protective immune response against Mycobacterium tuberculosis in mice. Immunity 2, 561-572. (doi:10.1016/1074-7613(95)90001-2)
14. Gardam, M. A., Keystone, E. C., Menzies, R., Manners, S., Skamene, E., Long, R. & Vinh, D. C. 2003 Antitumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management. Lancet Infect. Dis. 3, 148-155. (doi:10.1016/S1473-3099(03) 00545-0)
15. Sallusto, F., Geginat, J. & Lanzavecchia, A. 2004 Central memory and effector memory T cell subsets: function, generation, and maintenance. Annu. Rev. Immunol. 22, 745-763. (doi:10.1146/annurev.immunol. 22.012703.104702)
16. Sousa, A. O., Mazzaccaro, R. J., Russell, R. G., Lee, F. K., Turner, O. C., Hong, S., Luc, V. K. & Barry, R. B. 2000 Relative contributions of distinct MHC class Idependent cell populations in protection to tuberculosis infection in mice. Proc. Natl Acad. Sci. USA 97, 4204-4208. (doi:10.1073/pnas.97.8.4204)
17. van Pinxteren, L. A., Cassidy, J. P., Smedegaard, B. H., Agger, E. M. & Andersen, P. 2000 Control of latent Mycobacterium tuberculosis infection is dependent on CD8 T cells. Eur. J. Immunol. 30, 3689-3698. (doi:10. 1002/1521-4141(200012)30:12,3689::AID-IMMU36 89.3.0.CO;2-4)
18. 4+ T cell responses after vaccination and during Mycobacterium tuberculosis challenge. Nat. Immunol. 8, 369-377. (doi:10.1038/ni1449
19. Langermans, J. A. et al. 2001 Divergent effect of bacillus Calmette-Guerin (BCG) vaccination on Mycobacterium tuberculosis infection in highly related macaque species: implications for primate models in tuberculosis vaccine research. Proc. Natl Acad. Sci. USA 98, 11 497-11 502. (doi:10.1073/pnas.201404898)
20. Mittrucker, H. W., Steinhoff, U., Kohler, A., Krause, M., Lazar, D., Mex, P., Miekley, D. & Kaufmann, S. H. E. 2007 Poor correlation between BCG vaccination-induced T cell responses and protection against tuberculosis. Proc. Natl Acad. Sci. USA 104, 12 434-12 439. (doi:10.1073/pnas.0703510104)
21. Wedlock, D. N., Denis, M., Vordermeier, H. M., Hewinson, R. G. & Buddle, B. M. 2007 Vaccination of cattle with Danish and Pasteur strains of Mycobacterium bovis BCG induce different levels of IFNgamma post-vaccination, but induce similar levels of protection against bovine tuberculosis. Vet. Immunol. Immunopathol. 118, 50-58. (doi:10.1016/j.vetimm.2007.04.005)
22. Vordermeier, H. M. et al. 2009 Viral booster vaccines improve Mycobacterium bovis BCG-induced protection against bovine tuberculosis. Infect. Immun. 77, 3364-3373. (doi:10.1128/IAI.00287-09)
23. Kagina, B. M. et al. 2010 Specific T cell frequency and cytokine expression profile do not correlate with protection against tuberculosis, following BCG vaccination of newborns. Am. J. Respir. Crit. Care Med. 182, 1073-1079. (doi:10.1164/rccm.201003-0334OC)
24. Hesseling, A. C., Marais, B. J., Gie, R. P., Schaaf, H. S., Fine, P. E., Godfrey-Faussett, P. & Beyers, N. 2007 The risk of disseminated Bacille Calmette-Guerin (BCG) disease in HIV-infected children. Vaccine 25, 14-18. (doi:10.1016/j.vaccine.2006.07.020)
25. Hoft, D. F. et al. 2008 A new recombinant bacille Calmette-Guerin vaccine safely induces significantly enhanced tuberculosis-specific immunity in human volunteers. J. Infect. Dis. 198, 1491-1501. (doi:10.1086/592450)
26. Grode, L. et al. 2005 Increased vaccine efficacy against tuberculosis of recombinant Mycobacterium bovis bacille Calmette-Guerin mutants that secrete listeriolysin. J. Clin. Invest. 115, 2472-2479. (doi:10.1172/JCI24617)
27. Sun, R. et al. 2009 Novel recombinant BCG expressing perfringolysin O and the over-expression of key immunodominant antigens; pre-clinical characterization, safety and protection against challenge with Mycobacterium tuberculosis. Vaccine 27, 4412-4423. (doi:10.1016/j.vaccine. 2009.05.048)
28. von Reyn, C. F. et al. 2010 Prevention of tuberculosis in bacille Calmette-Guerin-primed, HIV-infected adults boosted with an inactivated whole-cell mycobacterial vaccine. AIDS 24, 675-685. (doi:10.1097/QAD. 0b013e3283350f1b)
29. Von Eschen, K. et al. 2009 The candidate tuberculosis vaccine Mtb72F/AS02A: tolerability and immunogenicity in humans. Hum. Vaccin. 5, 475-482.
30. van Dissel, J. T. et al. 2010 Ag85B-ESAT-6 adjuvanted with IC31 promotes strong and long-lived Mycobacterium tuberculosis specific T cell responses in naive human volunteers. Vaccine 28, 3571-3581. (doi:10.1016/j.vaccine. 2010.02.094)
31. Dietrich, J., Aagaard, C., Leah, R., Olsen, A. W., Stryhn, A., Doherty, T. M. & Andersen, P. 2005 Exchanging ESAT6 with TB10.4 in an Ag85B fusion moleculebased tuberculosis subunit vaccine: efficient protection and ESAT6-based sensitive monitoring of vaccine efficacy. J. Immunol. 174, 6332-6339.
32. 8+ T cells in adults. Am. J. Respir. Crit. Care Med. 181, 1407-1417. (doi:10.1164/rccm.200910-1484OC)
33. McShane, H., Pathan, A. A., Sander, C. R., Keating, S. M., Gilbert, S. C., Huygen, K., Fletcher, H. A. & Hill, A. V. S. 2004 Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCGprimed and naturally acquired antimycobacterial immunity in humans. Nat. Med. 10, 1240-1244. (doi:10. 1038/nm1128)
34. Scriba, T. J. et al. 2010 Modified vaccinia Ankaraexpressing Ag85A, a novel tuberculosis vaccine, is safe in adolescents and children, and induces polyfunctional CD4+ T cells. Eur. J. Immunol. 40, 279-290. (doi:10. 1002/eji.200939754)
35. Horwitz, M. A., Harth, G., Dillon, B. J. & Maslesa-Galic, S. 2000 Recombinant bacillus Calmette-Guerin (BCG) vaccines expressing the Mycobacterium tuberculosis 30-kDa major secretory protein induce greater protective immunity against tuberculosis than conventional BCG vaccines in a highly susceptible animal model. Proc. Natl Acad. Sci. USA 97, 13 853-13 858. (doi:10.1073/ pnas.250480397)
36. Martin, C. et al. 2006 The live Mycobacterium tuberculosis phoP mutant strain is more attenuated than BCG and confers protective immunity against tuberculosis in mice and guinea pigs. Vaccine 24, 3408-3419. (doi:10. 1016/j.vaccine.2006.03.017)
37. Larsen, M. H. et al. 2009 Efficacy and safety of live attenuated persistent and rapidly cleared Mycobacterium tuberculosis vaccine candidates in non-human primates. Vaccine 27, 4709-4717. (doi:10.1016/j.vaccine.2009. 05.050)
38. Walker, K. B. et al. 2010 The second Geneva consensus: recommendations for novel live TB vaccines. Vaccine 28, 2259-2270. (doi:10.1016/j.vaccine.2009.12.083)
39. Kamath, A. T. et al. 2005 New live mycobacterial vaccines: the Geneva consensus on essential steps towards clinical development. Vaccine 23, 3753-3761. (doi:10. 1016/j.vaccine.2005.03.001)
40. Stanford, J. L. et al. 1990 Mycobacterium vaccae in immunoprophylaxis and immunotherapy of leprosy and tuberculosis. Vaccine 8, 525-530. (doi:10.1016/0264-410X(90)90002-4)
41. Mayo, R. E. & Stanford, J. L. 2000 Double-blind placebo-controlled trial of Mycobacterium vaccae immunotherapy for tuberculosis in KwaZulu, South Africa, 1991-97. Trans. R. Soc. Trop. Med. Hyg. 94, 563-568. (doi:10.1016/S0035-9203(00)90088-9)
42. Skeiky, Y. A. et al. 2004 Differential immune responses and protective efficacy induced by components of a tuberculosis polyprotein vaccine, Mtb72F, delivered as naked DNA or recombinant protein. J. Immunol. 172, 7618-7628.
43. Leroux-Roels, I. et al. 2010 Evaluation of the safety and immunogenicity of two antigen concentrations of the Mtb72F/AS02(A) candidate tuberculosis vaccine in purified protein derivative-negative adults. Clin. Vaccine Immunol. 17, 1763-1771. (doi:10.1128/CVI.00133-10)
44. Dietrich, J., Andersen, C., Rappuoli, R., Doherty, T. M., Jensen, C. G. & Andersen, P. 2006 Mucosal administration of Ag85B-ESAT-6 protects against infection with Mycobacterium tuberculosis and boosts prior bacillus Calmette-Guerin immunity. J. Immunol. 177, 6353-6360.
45. Williams, A. et al. 2005 Evaluation of vaccines in the EU TB Vaccine Cluster using a guinea pig aerosol infection model of tuberculosis. Tuberculosis (Edinb). 85, 29-38. (doi:10.1016/j.tube.2004.09.009)
46. Pai, M., Riley, L. W. & Colford Jr, J. M. 2004 Interferongamma assays in the immunodiagnosis of tuberculosis: a systematic review. Lancet Infect. Dis. 4, 761-776. (doi:10. 1016/S1473-3099(04)01206-X)
47. Xiang, Z., Li, Y., Cun, A., Yang, W., Ellenberg, S., Switzer, W. M., Kalish, M. L. & Ertl, H. C. J. 2006 Chimpanzee adenovirus antibodies in humans, sub-Saharan Africa. Emerg. Infect. Dis. 12, 1596-1599.
48. Kostense, S. et al. 2004 Adenovirus types 5 and 35 seroprevalence in AIDS risk groups supports type 35 as a vaccine vector. AIDS 18, 1213-1216. (doi:10.1097/ 00002030-200405210-00019)
49. Radosevic, K. et al. 2007 Protective immune responses to a recombinant adenovirus type 35 tuberculosis vaccine in two mouse strains: CD4 and CD8 T-cell epitope mapping and role of gamma interferon. Infect. Immun. 75, 4105-4115. (doi:10.1128/IAI.00004-07)
50. Magalhaes, I. et al. 2008 rBCG induces strong antigenspecific T cell responses in rhesus macaques in a prime-boost setting with an adenovirus 35 tuberculosis vaccine vector. PLoS ONE 3, e3790. (doi:10.1371/ journal.pone.0003790)
51. Mayr, A., Stickl, H., Muller, H. K., Danner, K. & Singer, H. 1978 The smallpox vaccination strain MVA: marker, genetic structure, experience gained with the parenteral vaccination and behavior in organisms with a debilitated defence mechanism (author's Transl). Zentralbl. Bakteriol B 167, 375-390.
52. Goonetilleke, N. P., McShane, H., Hannan, C. M., Anderson, R. J., Brookes, R. H. & Hill, A. V. 2003 Enhanced immunogenicity and protective efficacy against Mycobacterium tuberculosis of bacille Calmette-Guerin vaccine using mucosal administration and boosting with a recombinant modified vaccinia virus Ankara. J. Immunol. 171, 1602-1609.
53. Williams, A., Goonetilleke, N. P., McShane, H., Clark, S. O., Hatch, G., Gilbert, S. C. & Hill, A. V. S. 2005 Boosting with poxviruses enhances Mycobacterium bovis BCG efficacy against tuberculosis in guinea pigs. Infect. Immun. 73, 3814-3816. (doi:10.1128/IAI.73.6.3814-3816.2005)
54. Verreck, F. A. et al. 2009 MVA.85A boosting of BCG and an attenuated, phoP deficient M. tuberculosis vaccine both show protective efficacy against tuberculosis in rhesus macaques. PLoS ONE 4, e5264. (doi:10.1371/journal. pone.0005264)
55. Buddle, B. M., Pollock, J. M., Skinner, M. A. & Wedlock, D. N. 2003 Development of vaccines to control bovine tuberculosis in cattle and relationship to vaccine development for other intracellular pathogens. Int. J. Parasitol. 33, 555-566. (doi:10.1016/S0020-7519(03) 00060-2)
56. Godkin, A. J., Thomas, H. C. & Openshaw, P. J. 2002 Evolution of epitope-specific memory CD4(+) T cells after clearance of hepatitis C virus. J. Immunol. 169, 2210-2214.
57. Koch, R. 1891 Forsetzung der Mitteilungen uber ein Heilmittel gegen Tuberkulose. Dtsch. Med. Wochenschr. 17, 101-102. (doi:10.1055/s-0029-1206198)
58. Taylor, J. L., Turner, O. C., Basaraba, R. J., Belisle, J. T., Huygen, K. & Orme, I. M. 2003 Pulmonary necrosis resulting from DNA vaccination against tuberculosis. Infect. Immun. 71, 2192-2198. (doi:10.1128/IAI.71.4. 2192-2198.2003)
59. Pathan, A. A. et al. 2007 Boosting BCG with recombinant modified vaccinia ankara expressing antigen 85A: different boosting intervals and implications for efficacy trials. PLoS ONE 2, e1052. (doi:10.1371/journal.pone. 0001052)
60. Whelan, K. T., Pathan, A. A., Sander, C. R., Fletcher, H. A., Poulton, I., Alder, N. C., Hill, A. V. S., McShane, H. & Kallas, E. G. 2009 Safety and immunogenicity of boosting BCG vaccinated subjects with BCG: comparison with boosting with a new TB vaccine, MVA85A. PLoS ONE 4, e5934. (doi:10.1371/journal.pone. 0005934)
61. 4+ memory T lymphocyte populations. Eur. J. Immunol. 37, 3089-3100. (doi:10.1002/eji.200737504)
62. Sander, C. R. et al. 2009 Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in Mycobacterium tuberculosis-infected individuals. Am. J. Respir. Crit. Care Med. 179, 724-733. (doi:10.1164/rccm.200809-1486OC)
63. Brookes, R. H. et al. 2008 Safety and immunogenicity of the candidate tuberculosis vaccine MVA85A in West Africa. PLoS ONE 3, e2921. (doi:10.1371/journal. pone.0002921)
64. Hawkridge, T. et al. 2008 Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in healthy adults in South Africa. J. Infect. Dis. 198, 544-552. (doi:10. 1086/590185)
65. Corbett, E. L., Watt, C. J., Walker, N., Maher, D., Williams, B. G., Raviglione, M. C. & Dye, C. 2003 The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch. Intern. Med. 163, 1009-1021. (doi:10.1001/archinte.163.9.1009)
66. Hawkridge, A. et al. 2008 Efficacy of percutaneous versus intradermal BCG in the prevention of tuberculosis in South African infants: randomised trial. Br. Med. J. 337, a2052. (doi:10.1136/bmj.a2052)